nodes	percent_of_prediction	percent_of_DWPC	metapath
Ziprasidone—ADRA1B—vas deferens—urinary bladder cancer	0.0516	0.192	CbGeAlD
Ziprasidone—HTR7—vas deferens—urinary bladder cancer	0.0301	0.112	CbGeAlD
Ziprasidone—CHRM3—ureter—urinary bladder cancer	0.0242	0.0898	CbGeAlD
Ziprasidone—CHRM3—muscle of abdomen—urinary bladder cancer	0.0174	0.0646	CbGeAlD
Ziprasidone—CYP1A2—urine—urinary bladder cancer	0.00597	0.0221	CbGeAlD
Ziprasidone—HTR2A—urine—urinary bladder cancer	0.00467	0.0173	CbGeAlD
Ziprasidone—H1F0—prostate gland—urinary bladder cancer	0.00435	0.0162	CbGeAlD
Ziprasidone—CYP3A4—urine—urinary bladder cancer	0.00432	0.016	CbGeAlD
Ziprasidone—CYP2D6—urine—urinary bladder cancer	0.00425	0.0158	CbGeAlD
Ziprasidone—CHRM5—epithelium—urinary bladder cancer	0.00371	0.0138	CbGeAlD
Ziprasidone—H1F0—seminal vesicle—urinary bladder cancer	0.00368	0.0137	CbGeAlD
Ziprasidone—CHRM2—prostate gland—urinary bladder cancer	0.00346	0.0129	CbGeAlD
Ziprasidone—CHRM1—prostate gland—urinary bladder cancer	0.00315	0.0117	CbGeAlD
Ziprasidone—ADRA1B—renal system—urinary bladder cancer	0.00314	0.0117	CbGeAlD
Ziprasidone—H1F0—smooth muscle tissue—urinary bladder cancer	0.00308	0.0114	CbGeAlD
Ziprasidone—DRD5—female reproductive system—urinary bladder cancer	0.00307	0.0114	CbGeAlD
Ziprasidone—H1F0—renal system—urinary bladder cancer	0.00297	0.011	CbGeAlD
Ziprasidone—H1F0—urethra—urinary bladder cancer	0.00291	0.0108	CbGeAlD
Ziprasidone—CHRM3—prostate gland—urinary bladder cancer	0.00282	0.0105	CbGeAlD
Ziprasidone—ADRA1A—prostate gland—urinary bladder cancer	0.00259	0.00962	CbGeAlD
Ziprasidone—KCNH2—prostate gland—urinary bladder cancer	0.0025	0.00929	CbGeAlD
Ziprasidone—ADRA2C—prostate gland—urinary bladder cancer	0.00247	0.00916	CbGeAlD
Ziprasidone—H1F0—female reproductive system—urinary bladder cancer	0.00238	0.00882	CbGeAlD
Ziprasidone—H1F0—vagina—urinary bladder cancer	0.00215	0.00798	CbGeAlD
Ziprasidone—KCNH2—seminal vesicle—urinary bladder cancer	0.00212	0.00786	CbGeAlD
Ziprasidone—ADRA2C—seminal vesicle—urinary bladder cancer	0.00209	0.00775	CbGeAlD
Ziprasidone—CYP3A5—prostate gland—urinary bladder cancer	0.00207	0.00767	CbGeAlD
Ziprasidone—HRH1—prostate gland—urinary bladder cancer	0.00201	0.00744	CbGeAlD
Ziprasidone—CHRM3—smooth muscle tissue—urinary bladder cancer	0.002	0.00742	CbGeAlD
Ziprasidone—HTR7—epithelium—urinary bladder cancer	0.00197	0.00733	CbGeAlD
Ziprasidone—ADRA2A—prostate gland—urinary bladder cancer	0.00197	0.00731	CbGeAlD
Ziprasidone—CHRM3—renal system—urinary bladder cancer	0.00192	0.00714	CbGeAlD
Ziprasidone—HTR1A—renal system—urinary bladder cancer	0.00192	0.00711	CbGeAlD
Ziprasidone—ADRA1A—epithelium—urinary bladder cancer	0.0019	0.00707	CbGeAlD
Ziprasidone—HTR7—smooth muscle tissue—urinary bladder cancer	0.0019	0.00706	CbGeAlD
Ziprasidone—HTR1B—female reproductive system—urinary bladder cancer	0.0019	0.00706	CbGeAlD
Ziprasidone—CHRM3—urethra—urinary bladder cancer	0.00189	0.00701	CbGeAlD
Ziprasidone—HTR1D—female reproductive system—urinary bladder cancer	0.00184	0.00683	CbGeAlD
Ziprasidone—HTR7—renal system—urinary bladder cancer	0.00183	0.00679	CbGeAlD
Ziprasidone—HTR2C—female reproductive system—urinary bladder cancer	0.00182	0.00676	CbGeAlD
Ziprasidone—ADRA1A—renal system—urinary bladder cancer	0.00177	0.00655	CbGeAlD
Ziprasidone—SLC6A4—female reproductive system—urinary bladder cancer	0.00173	0.00641	CbGeAlD
Ziprasidone—CHRM1—female reproductive system—urinary bladder cancer	0.00172	0.00639	CbGeAlD
Ziprasidone—KCNH2—renal system—urinary bladder cancer	0.00171	0.00633	CbGeAlD
Ziprasidone—ADRA2C—renal system—urinary bladder cancer	0.00168	0.00625	CbGeAlD
Ziprasidone—KCNH2—urethra—urinary bladder cancer	0.00168	0.00622	CbGeAlD
Ziprasidone—ADRA2A—seminal vesicle—urinary bladder cancer	0.00167	0.00618	CbGeAlD
Ziprasidone—ADRA2C—urethra—urinary bladder cancer	0.00165	0.00613	CbGeAlD
Ziprasidone—CHRM3—female reproductive system—urinary bladder cancer	0.00154	0.00572	CbGeAlD
Ziprasidone—HRH1—epithelium—urinary bladder cancer	0.00147	0.00547	CbGeAlD
Ziprasidone—HTR7—female reproductive system—urinary bladder cancer	0.00147	0.00544	CbGeAlD
Ziprasidone—CYP1A2—renal system—urinary bladder cancer	0.00146	0.00542	CbGeAlD
Ziprasidone—HRH1—smooth muscle tissue—urinary bladder cancer	0.00142	0.00527	CbGeAlD
Ziprasidone—CYP3A5—renal system—urinary bladder cancer	0.00141	0.00523	CbGeAlD
Ziprasidone—H1F0—lymph node—urinary bladder cancer	0.00139	0.00516	CbGeAlD
Ziprasidone—KCNH2—female reproductive system—urinary bladder cancer	0.00137	0.00507	CbGeAlD
Ziprasidone—HRH1—urethra—urinary bladder cancer	0.00134	0.00498	CbGeAlD
Ziprasidone—ADRA2A—urethra—urinary bladder cancer	0.00132	0.0049	CbGeAlD
Ziprasidone—KCNH2—vagina—urinary bladder cancer	0.00124	0.00458	CbGeAlD
Ziprasidone—HTR2A—epithelium—urinary bladder cancer	0.00123	0.00457	CbGeAlD
Ziprasidone—ADRA2C—vagina—urinary bladder cancer	0.00122	0.00452	CbGeAlD
Ziprasidone—HTR2A—smooth muscle tissue—urinary bladder cancer	0.00119	0.0044	CbGeAlD
Ziprasidone—HTR2A—renal system—urinary bladder cancer	0.00114	0.00424	CbGeAlD
Ziprasidone—HRH1—female reproductive system—urinary bladder cancer	0.00109	0.00406	CbGeAlD
Ziprasidone—ADRA2A—female reproductive system—urinary bladder cancer	0.00108	0.00399	CbGeAlD
Ziprasidone—CYP3A4—renal system—urinary bladder cancer	0.00106	0.00392	CbGeAlD
Ziprasidone—CYP2D6—renal system—urinary bladder cancer	0.00104	0.00386	CbGeAlD
Ziprasidone—CYP3A5—vagina—urinary bladder cancer	0.00102	0.00379	CbGeAlD
Ziprasidone—HRH1—vagina—urinary bladder cancer	0.00099	0.00367	CbGeAlD
Ziprasidone—ADRA2A—vagina—urinary bladder cancer	0.000972	0.00361	CbGeAlD
Ziprasidone—HTR2A—female reproductive system—urinary bladder cancer	0.000914	0.00339	CbGeAlD
Ziprasidone—CYP3A4—female reproductive system—urinary bladder cancer	0.000846	0.00314	CbGeAlD
Ziprasidone—CYP2D6—female reproductive system—urinary bladder cancer	0.000833	0.00309	CbGeAlD
Ziprasidone—HTR2A—vagina—urinary bladder cancer	0.000827	0.00307	CbGeAlD
Ziprasidone—KCNH2—lymph node—urinary bladder cancer	0.000799	0.00297	CbGeAlD
Ziprasidone—ADRA2C—lymph node—urinary bladder cancer	0.000788	0.00293	CbGeAlD
Ziprasidone—HRH1—lymph node—urinary bladder cancer	0.00064	0.00238	CbGeAlD
Ziprasidone—ADRA2A—lymph node—urinary bladder cancer	0.000629	0.00233	CbGeAlD
Ziprasidone—Pneumonia—Doxorubicin—urinary bladder cancer	0.000272	0.000455	CcSEcCtD
Ziprasidone—Gastrointestinal pain—Etoposide—urinary bladder cancer	0.000272	0.000455	CcSEcCtD
Ziprasidone—Infestation NOS—Doxorubicin—urinary bladder cancer	0.000271	0.000453	CcSEcCtD
Ziprasidone—Infestation—Doxorubicin—urinary bladder cancer	0.000271	0.000453	CcSEcCtD
Ziprasidone—Visual impairment—Methotrexate—urinary bladder cancer	0.000271	0.000452	CcSEcCtD
Ziprasidone—Hypersensitivity—Cisplatin—urinary bladder cancer	0.000268	0.000448	CcSEcCtD
Ziprasidone—Bradycardia—Epirubicin—urinary bladder cancer	0.000268	0.000447	CcSEcCtD
Ziprasidone—Diarrhoea—Gemcitabine—urinary bladder cancer	0.000267	0.000446	CcSEcCtD
Ziprasidone—Renal failure—Doxorubicin—urinary bladder cancer	0.000266	0.000445	CcSEcCtD
Ziprasidone—Neuropathy peripheral—Doxorubicin—urinary bladder cancer	0.000265	0.000444	CcSEcCtD
Ziprasidone—Urticaria—Etoposide—urinary bladder cancer	0.000265	0.000442	CcSEcCtD
Ziprasidone—Haemoglobin—Epirubicin—urinary bladder cancer	0.000264	0.000441	CcSEcCtD
Ziprasidone—Jaundice—Doxorubicin—urinary bladder cancer	0.000264	0.000441	CcSEcCtD
Ziprasidone—Rhinitis—Epirubicin—urinary bladder cancer	0.000263	0.00044	CcSEcCtD
Ziprasidone—Abdominal pain—Etoposide—urinary bladder cancer	0.000263	0.00044	CcSEcCtD
Ziprasidone—Body temperature increased—Etoposide—urinary bladder cancer	0.000263	0.00044	CcSEcCtD
Ziprasidone—Conjunctivitis—Doxorubicin—urinary bladder cancer	0.000263	0.00044	CcSEcCtD
Ziprasidone—Haemorrhage—Epirubicin—urinary bladder cancer	0.000263	0.000439	CcSEcCtD
Ziprasidone—Hepatitis—Epirubicin—urinary bladder cancer	0.000263	0.000439	CcSEcCtD
Ziprasidone—Eye disorder—Methotrexate—urinary bladder cancer	0.000262	0.000439	CcSEcCtD
Ziprasidone—Diarrhoea—Fluorouracil—urinary bladder cancer	0.000262	0.000439	CcSEcCtD
Ziprasidone—Tinnitus—Methotrexate—urinary bladder cancer	0.000262	0.000438	CcSEcCtD
Ziprasidone—Hypoaesthesia—Epirubicin—urinary bladder cancer	0.000261	0.000437	CcSEcCtD
Ziprasidone—Asthenia—Cisplatin—urinary bladder cancer	0.000261	0.000436	CcSEcCtD
Ziprasidone—Pharyngitis—Epirubicin—urinary bladder cancer	0.000261	0.000436	CcSEcCtD
Ziprasidone—Cardiac disorder—Methotrexate—urinary bladder cancer	0.000261	0.000436	CcSEcCtD
Ziprasidone—Sweating—Doxorubicin—urinary bladder cancer	0.00026	0.000434	CcSEcCtD
Ziprasidone—Urinary tract disorder—Epirubicin—urinary bladder cancer	0.000259	0.000434	CcSEcCtD
Ziprasidone—Oedema peripheral—Epirubicin—urinary bladder cancer	0.000259	0.000433	CcSEcCtD
Ziprasidone—Haematuria—Doxorubicin—urinary bladder cancer	0.000258	0.000432	CcSEcCtD
Ziprasidone—Connective tissue disorder—Epirubicin—urinary bladder cancer	0.000258	0.000432	CcSEcCtD
Ziprasidone—Urethral disorder—Epirubicin—urinary bladder cancer	0.000258	0.000431	CcSEcCtD
Ziprasidone—Epistaxis—Doxorubicin—urinary bladder cancer	0.000255	0.000427	CcSEcCtD
Ziprasidone—Angiopathy—Methotrexate—urinary bladder cancer	0.000255	0.000426	CcSEcCtD
Ziprasidone—Immune system disorder—Methotrexate—urinary bladder cancer	0.000254	0.000424	CcSEcCtD
Ziprasidone—Dizziness—Fluorouracil—urinary bladder cancer	0.000254	0.000424	CcSEcCtD
Ziprasidone—Visual impairment—Epirubicin—urinary bladder cancer	0.000253	0.000423	CcSEcCtD
Ziprasidone—Mediastinal disorder—Methotrexate—urinary bladder cancer	0.000253	0.000423	CcSEcCtD
Ziprasidone—Chills—Methotrexate—urinary bladder cancer	0.000252	0.000421	CcSEcCtD
Ziprasidone—Diarrhoea—Cisplatin—urinary bladder cancer	0.000249	0.000416	CcSEcCtD
Ziprasidone—Alopecia—Methotrexate—urinary bladder cancer	0.000248	0.000415	CcSEcCtD
Ziprasidone—Vomiting—Gemcitabine—urinary bladder cancer	0.000248	0.000414	CcSEcCtD
Ziprasidone—Bradycardia—Doxorubicin—urinary bladder cancer	0.000248	0.000414	CcSEcCtD
Ziprasidone—Mental disorder—Methotrexate—urinary bladder cancer	0.000246	0.000411	CcSEcCtD
Ziprasidone—Rash—Gemcitabine—urinary bladder cancer	0.000246	0.000411	CcSEcCtD
Ziprasidone—Dermatitis—Gemcitabine—urinary bladder cancer	0.000246	0.000411	CcSEcCtD
Ziprasidone—Eye disorder—Epirubicin—urinary bladder cancer	0.000246	0.00041	CcSEcCtD
Ziprasidone—Hypersensitivity—Etoposide—urinary bladder cancer	0.000245	0.00041	CcSEcCtD
Ziprasidone—Tinnitus—Epirubicin—urinary bladder cancer	0.000245	0.000409	CcSEcCtD
Ziprasidone—Erythema—Methotrexate—urinary bladder cancer	0.000244	0.000409	CcSEcCtD
Ziprasidone—Malnutrition—Methotrexate—urinary bladder cancer	0.000244	0.000409	CcSEcCtD
Ziprasidone—Haemoglobin—Doxorubicin—urinary bladder cancer	0.000244	0.000408	CcSEcCtD
Ziprasidone—Headache—Gemcitabine—urinary bladder cancer	0.000244	0.000408	CcSEcCtD
Ziprasidone—Cardiac disorder—Epirubicin—urinary bladder cancer	0.000244	0.000408	CcSEcCtD
Ziprasidone—Vomiting—Fluorouracil—urinary bladder cancer	0.000244	0.000408	CcSEcCtD
Ziprasidone—Rhinitis—Doxorubicin—urinary bladder cancer	0.000244	0.000407	CcSEcCtD
Ziprasidone—Haemorrhage—Doxorubicin—urinary bladder cancer	0.000243	0.000406	CcSEcCtD
Ziprasidone—Hepatitis—Doxorubicin—urinary bladder cancer	0.000243	0.000406	CcSEcCtD
Ziprasidone—Hypoaesthesia—Doxorubicin—urinary bladder cancer	0.000242	0.000404	CcSEcCtD
Ziprasidone—Rash—Fluorouracil—urinary bladder cancer	0.000242	0.000404	CcSEcCtD
Ziprasidone—Dermatitis—Fluorouracil—urinary bladder cancer	0.000242	0.000404	CcSEcCtD
Ziprasidone—Pharyngitis—Doxorubicin—urinary bladder cancer	0.000241	0.000403	CcSEcCtD
Ziprasidone—Headache—Fluorouracil—urinary bladder cancer	0.00024	0.000402	CcSEcCtD
Ziprasidone—Urinary tract disorder—Doxorubicin—urinary bladder cancer	0.00024	0.000401	CcSEcCtD
Ziprasidone—Oedema peripheral—Doxorubicin—urinary bladder cancer	0.00024	0.0004	CcSEcCtD
Ziprasidone—Asthenia—Etoposide—urinary bladder cancer	0.000239	0.000399	CcSEcCtD
Ziprasidone—Connective tissue disorder—Doxorubicin—urinary bladder cancer	0.000239	0.000399	CcSEcCtD
Ziprasidone—Angiopathy—Epirubicin—urinary bladder cancer	0.000238	0.000398	CcSEcCtD
Ziprasidone—Urethral disorder—Doxorubicin—urinary bladder cancer	0.000238	0.000398	CcSEcCtD
Ziprasidone—Immune system disorder—Epirubicin—urinary bladder cancer	0.000237	0.000397	CcSEcCtD
Ziprasidone—Mediastinal disorder—Epirubicin—urinary bladder cancer	0.000237	0.000396	CcSEcCtD
Ziprasidone—Back pain—Methotrexate—urinary bladder cancer	0.000236	0.000395	CcSEcCtD
Ziprasidone—Chills—Epirubicin—urinary bladder cancer	0.000236	0.000394	CcSEcCtD
Ziprasidone—Arrhythmia—Epirubicin—urinary bladder cancer	0.000235	0.000392	CcSEcCtD
Ziprasidone—Visual impairment—Doxorubicin—urinary bladder cancer	0.000234	0.000392	CcSEcCtD
Ziprasidone—Alopecia—Epirubicin—urinary bladder cancer	0.000232	0.000388	CcSEcCtD
Ziprasidone—Nausea—Gemcitabine—urinary bladder cancer	0.000232	0.000387	CcSEcCtD
Ziprasidone—Vomiting—Cisplatin—urinary bladder cancer	0.000231	0.000386	CcSEcCtD
Ziprasidone—Vision blurred—Methotrexate—urinary bladder cancer	0.00023	0.000385	CcSEcCtD
Ziprasidone—Mental disorder—Epirubicin—urinary bladder cancer	0.00023	0.000385	CcSEcCtD
Ziprasidone—Rash—Cisplatin—urinary bladder cancer	0.000229	0.000383	CcSEcCtD
Ziprasidone—Dermatitis—Cisplatin—urinary bladder cancer	0.000229	0.000383	CcSEcCtD
Ziprasidone—Malnutrition—Epirubicin—urinary bladder cancer	0.000229	0.000382	CcSEcCtD
Ziprasidone—Erythema—Epirubicin—urinary bladder cancer	0.000229	0.000382	CcSEcCtD
Ziprasidone—Diarrhoea—Etoposide—urinary bladder cancer	0.000228	0.000381	CcSEcCtD
Ziprasidone—Nausea—Fluorouracil—urinary bladder cancer	0.000228	0.000381	CcSEcCtD
Ziprasidone—Eye disorder—Doxorubicin—urinary bladder cancer	0.000227	0.00038	CcSEcCtD
Ziprasidone—Tinnitus—Doxorubicin—urinary bladder cancer	0.000227	0.000379	CcSEcCtD
Ziprasidone—Anaemia—Methotrexate—urinary bladder cancer	0.000226	0.000378	CcSEcCtD
Ziprasidone—Cardiac disorder—Doxorubicin—urinary bladder cancer	0.000226	0.000377	CcSEcCtD
Ziprasidone—Flatulence—Epirubicin—urinary bladder cancer	0.000225	0.000377	CcSEcCtD
Ziprasidone—Back pain—Epirubicin—urinary bladder cancer	0.000221	0.00037	CcSEcCtD
Ziprasidone—Angiopathy—Doxorubicin—urinary bladder cancer	0.000221	0.000369	CcSEcCtD
Ziprasidone—Dizziness—Etoposide—urinary bladder cancer	0.00022	0.000368	CcSEcCtD
Ziprasidone—Muscle spasms—Epirubicin—urinary bladder cancer	0.00022	0.000368	CcSEcCtD
Ziprasidone—Immune system disorder—Doxorubicin—urinary bladder cancer	0.00022	0.000367	CcSEcCtD
Ziprasidone—Vertigo—Methotrexate—urinary bladder cancer	0.00022	0.000367	CcSEcCtD
Ziprasidone—Mediastinal disorder—Doxorubicin—urinary bladder cancer	0.000219	0.000366	CcSEcCtD
Ziprasidone—Leukopenia—Methotrexate—urinary bladder cancer	0.000219	0.000366	CcSEcCtD
Ziprasidone—Chills—Doxorubicin—urinary bladder cancer	0.000218	0.000365	CcSEcCtD
Ziprasidone—Arrhythmia—Doxorubicin—urinary bladder cancer	0.000217	0.000363	CcSEcCtD
Ziprasidone—Nausea—Cisplatin—urinary bladder cancer	0.000216	0.000361	CcSEcCtD
Ziprasidone—Vision blurred—Epirubicin—urinary bladder cancer	0.000216	0.00036	CcSEcCtD
Ziprasidone—Alopecia—Doxorubicin—urinary bladder cancer	0.000215	0.000359	CcSEcCtD
Ziprasidone—Cough—Methotrexate—urinary bladder cancer	0.000213	0.000356	CcSEcCtD
Ziprasidone—Mental disorder—Doxorubicin—urinary bladder cancer	0.000213	0.000356	CcSEcCtD
Ziprasidone—Vomiting—Etoposide—urinary bladder cancer	0.000212	0.000354	CcSEcCtD
Ziprasidone—Erythema—Doxorubicin—urinary bladder cancer	0.000212	0.000354	CcSEcCtD
Ziprasidone—Malnutrition—Doxorubicin—urinary bladder cancer	0.000212	0.000354	CcSEcCtD
Ziprasidone—Anaemia—Epirubicin—urinary bladder cancer	0.000211	0.000353	CcSEcCtD
Ziprasidone—Agitation—Epirubicin—urinary bladder cancer	0.00021	0.000351	CcSEcCtD
Ziprasidone—Rash—Etoposide—urinary bladder cancer	0.00021	0.000351	CcSEcCtD
Ziprasidone—Dermatitis—Etoposide—urinary bladder cancer	0.00021	0.000351	CcSEcCtD
Ziprasidone—Headache—Etoposide—urinary bladder cancer	0.000209	0.000349	CcSEcCtD
Ziprasidone—Flatulence—Doxorubicin—urinary bladder cancer	0.000209	0.000349	CcSEcCtD
Ziprasidone—Arthralgia—Methotrexate—urinary bladder cancer	0.000208	0.000348	CcSEcCtD
Ziprasidone—Chest pain—Methotrexate—urinary bladder cancer	0.000208	0.000348	CcSEcCtD
Ziprasidone—Myalgia—Methotrexate—urinary bladder cancer	0.000208	0.000348	CcSEcCtD
Ziprasidone—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—urinary bladder cancer	0.000207	0.000345	CcSEcCtD
Ziprasidone—Vertigo—Epirubicin—urinary bladder cancer	0.000206	0.000343	CcSEcCtD
Ziprasidone—Syncope—Epirubicin—urinary bladder cancer	0.000205	0.000343	CcSEcCtD
Ziprasidone—Leukopenia—Epirubicin—urinary bladder cancer	0.000205	0.000342	CcSEcCtD
Ziprasidone—Back pain—Doxorubicin—urinary bladder cancer	0.000205	0.000342	CcSEcCtD
Ziprasidone—Muscle spasms—Doxorubicin—urinary bladder cancer	0.000203	0.00034	CcSEcCtD
Ziprasidone—Palpitations—Epirubicin—urinary bladder cancer	0.000202	0.000338	CcSEcCtD
Ziprasidone—Confusional state—Methotrexate—urinary bladder cancer	0.000201	0.000336	CcSEcCtD
Ziprasidone—Loss of consciousness—Epirubicin—urinary bladder cancer	0.000201	0.000336	CcSEcCtD
Ziprasidone—Cough—Epirubicin—urinary bladder cancer	0.0002	0.000334	CcSEcCtD
Ziprasidone—Vision blurred—Doxorubicin—urinary bladder cancer	0.000199	0.000333	CcSEcCtD
Ziprasidone—Infection—Methotrexate—urinary bladder cancer	0.000198	0.000331	CcSEcCtD
Ziprasidone—Nausea—Etoposide—urinary bladder cancer	0.000198	0.000331	CcSEcCtD
Ziprasidone—Hypertension—Epirubicin—urinary bladder cancer	0.000197	0.00033	CcSEcCtD
Ziprasidone—Nervous system disorder—Methotrexate—urinary bladder cancer	0.000196	0.000327	CcSEcCtD
Ziprasidone—Anaemia—Doxorubicin—urinary bladder cancer	0.000196	0.000327	CcSEcCtD
Ziprasidone—Thrombocytopenia—Methotrexate—urinary bladder cancer	0.000195	0.000326	CcSEcCtD
Ziprasidone—Chest pain—Epirubicin—urinary bladder cancer	0.000195	0.000325	CcSEcCtD
Ziprasidone—Arthralgia—Epirubicin—urinary bladder cancer	0.000195	0.000325	CcSEcCtD
Ziprasidone—Myalgia—Epirubicin—urinary bladder cancer	0.000195	0.000325	CcSEcCtD
Ziprasidone—Agitation—Doxorubicin—urinary bladder cancer	0.000194	0.000325	CcSEcCtD
Ziprasidone—Anxiety—Epirubicin—urinary bladder cancer	0.000194	0.000324	CcSEcCtD
Ziprasidone—Skin disorder—Methotrexate—urinary bladder cancer	0.000194	0.000324	CcSEcCtD
Ziprasidone—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—urinary bladder cancer	0.000193	0.000323	CcSEcCtD
Ziprasidone—Hyperhidrosis—Methotrexate—urinary bladder cancer	0.000193	0.000322	CcSEcCtD
Ziprasidone—Dry mouth—Epirubicin—urinary bladder cancer	0.00019	0.000318	CcSEcCtD
Ziprasidone—Vertigo—Doxorubicin—urinary bladder cancer	0.00019	0.000318	CcSEcCtD
Ziprasidone—Anorexia—Methotrexate—urinary bladder cancer	0.00019	0.000318	CcSEcCtD
Ziprasidone—Syncope—Doxorubicin—urinary bladder cancer	0.00019	0.000317	CcSEcCtD
Ziprasidone—Leukopenia—Doxorubicin—urinary bladder cancer	0.000189	0.000317	CcSEcCtD
Ziprasidone—Confusional state—Epirubicin—urinary bladder cancer	0.000188	0.000315	CcSEcCtD
Ziprasidone—Palpitations—Doxorubicin—urinary bladder cancer	0.000187	0.000313	CcSEcCtD
Ziprasidone—Hypotension—Methotrexate—urinary bladder cancer	0.000186	0.000312	CcSEcCtD
Ziprasidone—Loss of consciousness—Doxorubicin—urinary bladder cancer	0.000186	0.000311	CcSEcCtD
Ziprasidone—Infection—Epirubicin—urinary bladder cancer	0.000185	0.00031	CcSEcCtD
Ziprasidone—Cough—Doxorubicin—urinary bladder cancer	0.000185	0.000309	CcSEcCtD
Ziprasidone—Shock—Epirubicin—urinary bladder cancer	0.000184	0.000307	CcSEcCtD
Ziprasidone—Nervous system disorder—Epirubicin—urinary bladder cancer	0.000183	0.000306	CcSEcCtD
Ziprasidone—Thrombocytopenia—Epirubicin—urinary bladder cancer	0.000183	0.000305	CcSEcCtD
Ziprasidone—Hypertension—Doxorubicin—urinary bladder cancer	0.000183	0.000305	CcSEcCtD
Ziprasidone—Tachycardia—Epirubicin—urinary bladder cancer	0.000182	0.000305	CcSEcCtD
Ziprasidone—Musculoskeletal discomfort—Methotrexate—urinary bladder cancer	0.000182	0.000304	CcSEcCtD
Ziprasidone—Skin disorder—Epirubicin—urinary bladder cancer	0.000181	0.000303	CcSEcCtD
Ziprasidone—Hyperhidrosis—Epirubicin—urinary bladder cancer	0.00018	0.000302	CcSEcCtD
Ziprasidone—Insomnia—Methotrexate—urinary bladder cancer	0.00018	0.000302	CcSEcCtD
Ziprasidone—Arthralgia—Doxorubicin—urinary bladder cancer	0.00018	0.000301	CcSEcCtD
Ziprasidone—Myalgia—Doxorubicin—urinary bladder cancer	0.00018	0.000301	CcSEcCtD
Ziprasidone—Chest pain—Doxorubicin—urinary bladder cancer	0.00018	0.000301	CcSEcCtD
Ziprasidone—Anxiety—Doxorubicin—urinary bladder cancer	0.00018	0.0003	CcSEcCtD
Ziprasidone—Paraesthesia—Methotrexate—urinary bladder cancer	0.000179	0.000299	CcSEcCtD
Ziprasidone—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—urinary bladder cancer	0.000179	0.000299	CcSEcCtD
Ziprasidone—Anorexia—Epirubicin—urinary bladder cancer	0.000178	0.000297	CcSEcCtD
Ziprasidone—Dyspnoea—Methotrexate—urinary bladder cancer	0.000178	0.000297	CcSEcCtD
Ziprasidone—Somnolence—Methotrexate—urinary bladder cancer	0.000177	0.000296	CcSEcCtD
Ziprasidone—Dry mouth—Doxorubicin—urinary bladder cancer	0.000176	0.000295	CcSEcCtD
Ziprasidone—Dyspepsia—Methotrexate—urinary bladder cancer	0.000176	0.000293	CcSEcCtD
Ziprasidone—Hypotension—Epirubicin—urinary bladder cancer	0.000174	0.000292	CcSEcCtD
Ziprasidone—Confusional state—Doxorubicin—urinary bladder cancer	0.000174	0.000291	CcSEcCtD
Ziprasidone—Decreased appetite—Methotrexate—urinary bladder cancer	0.000173	0.00029	CcSEcCtD
Ziprasidone—Gastrointestinal disorder—Methotrexate—urinary bladder cancer	0.000172	0.000288	CcSEcCtD
Ziprasidone—Fatigue—Methotrexate—urinary bladder cancer	0.000172	0.000287	CcSEcCtD
Ziprasidone—Infection—Doxorubicin—urinary bladder cancer	0.000172	0.000287	CcSEcCtD
Ziprasidone—Musculoskeletal discomfort—Epirubicin—urinary bladder cancer	0.00017	0.000284	CcSEcCtD
Ziprasidone—Shock—Doxorubicin—urinary bladder cancer	0.00017	0.000284	CcSEcCtD
Ziprasidone—Nervous system disorder—Doxorubicin—urinary bladder cancer	0.000169	0.000283	CcSEcCtD
Ziprasidone—Thrombocytopenia—Doxorubicin—urinary bladder cancer	0.000169	0.000283	CcSEcCtD
Ziprasidone—Insomnia—Epirubicin—urinary bladder cancer	0.000169	0.000282	CcSEcCtD
Ziprasidone—Tachycardia—Doxorubicin—urinary bladder cancer	0.000169	0.000282	CcSEcCtD
Ziprasidone—Skin disorder—Doxorubicin—urinary bladder cancer	0.000168	0.00028	CcSEcCtD
Ziprasidone—Paraesthesia—Epirubicin—urinary bladder cancer	0.000168	0.00028	CcSEcCtD
Ziprasidone—Hyperhidrosis—Doxorubicin—urinary bladder cancer	0.000167	0.000279	CcSEcCtD
Ziprasidone—Dyspnoea—Epirubicin—urinary bladder cancer	0.000166	0.000278	CcSEcCtD
Ziprasidone—Somnolence—Epirubicin—urinary bladder cancer	0.000166	0.000277	CcSEcCtD
Ziprasidone—Anorexia—Doxorubicin—urinary bladder cancer	0.000165	0.000275	CcSEcCtD
Ziprasidone—Feeling abnormal—Methotrexate—urinary bladder cancer	0.000164	0.000275	CcSEcCtD
Ziprasidone—Dyspepsia—Epirubicin—urinary bladder cancer	0.000164	0.000275	CcSEcCtD
Ziprasidone—Gastrointestinal pain—Methotrexate—urinary bladder cancer	0.000163	0.000273	CcSEcCtD
Ziprasidone—Decreased appetite—Epirubicin—urinary bladder cancer	0.000162	0.000271	CcSEcCtD
Ziprasidone—Hypotension—Doxorubicin—urinary bladder cancer	0.000161	0.00027	CcSEcCtD
Ziprasidone—Gastrointestinal disorder—Epirubicin—urinary bladder cancer	0.000161	0.000269	CcSEcCtD
Ziprasidone—Fatigue—Epirubicin—urinary bladder cancer	0.000161	0.000269	CcSEcCtD
Ziprasidone—Constipation—Epirubicin—urinary bladder cancer	0.00016	0.000267	CcSEcCtD
Ziprasidone—Urticaria—Methotrexate—urinary bladder cancer	0.000158	0.000265	CcSEcCtD
Ziprasidone—Abdominal pain—Methotrexate—urinary bladder cancer	0.000158	0.000264	CcSEcCtD
Ziprasidone—Body temperature increased—Methotrexate—urinary bladder cancer	0.000158	0.000264	CcSEcCtD
Ziprasidone—Musculoskeletal discomfort—Doxorubicin—urinary bladder cancer	0.000157	0.000263	CcSEcCtD
Ziprasidone—Insomnia—Doxorubicin—urinary bladder cancer	0.000156	0.000261	CcSEcCtD
Ziprasidone—Paraesthesia—Doxorubicin—urinary bladder cancer	0.000155	0.000259	CcSEcCtD
Ziprasidone—Dyspnoea—Doxorubicin—urinary bladder cancer	0.000154	0.000257	CcSEcCtD
Ziprasidone—Feeling abnormal—Epirubicin—urinary bladder cancer	0.000154	0.000257	CcSEcCtD
Ziprasidone—Somnolence—Doxorubicin—urinary bladder cancer	0.000154	0.000257	CcSEcCtD
Ziprasidone—Gastrointestinal pain—Epirubicin—urinary bladder cancer	0.000153	0.000255	CcSEcCtD
Ziprasidone—Dyspepsia—Doxorubicin—urinary bladder cancer	0.000152	0.000254	CcSEcCtD
Ziprasidone—Decreased appetite—Doxorubicin—urinary bladder cancer	0.00015	0.000251	CcSEcCtD
Ziprasidone—Gastrointestinal disorder—Doxorubicin—urinary bladder cancer	0.000149	0.000249	CcSEcCtD
Ziprasidone—Fatigue—Doxorubicin—urinary bladder cancer	0.000149	0.000249	CcSEcCtD
Ziprasidone—Urticaria—Epirubicin—urinary bladder cancer	0.000148	0.000248	CcSEcCtD
Ziprasidone—Constipation—Doxorubicin—urinary bladder cancer	0.000148	0.000247	CcSEcCtD
Ziprasidone—Abdominal pain—Epirubicin—urinary bladder cancer	0.000148	0.000247	CcSEcCtD
Ziprasidone—Body temperature increased—Epirubicin—urinary bladder cancer	0.000148	0.000247	CcSEcCtD
Ziprasidone—Hypersensitivity—Methotrexate—urinary bladder cancer	0.000147	0.000246	CcSEcCtD
Ziprasidone—Asthenia—Methotrexate—urinary bladder cancer	0.000143	0.000239	CcSEcCtD
Ziprasidone—Feeling abnormal—Doxorubicin—urinary bladder cancer	0.000142	0.000238	CcSEcCtD
Ziprasidone—Gastrointestinal pain—Doxorubicin—urinary bladder cancer	0.000141	0.000236	CcSEcCtD
Ziprasidone—Hypersensitivity—Epirubicin—urinary bladder cancer	0.000138	0.00023	CcSEcCtD
Ziprasidone—Urticaria—Doxorubicin—urinary bladder cancer	0.000137	0.000229	CcSEcCtD
Ziprasidone—Abdominal pain—Doxorubicin—urinary bladder cancer	0.000137	0.000228	CcSEcCtD
Ziprasidone—Body temperature increased—Doxorubicin—urinary bladder cancer	0.000137	0.000228	CcSEcCtD
Ziprasidone—Diarrhoea—Methotrexate—urinary bladder cancer	0.000136	0.000228	CcSEcCtD
Ziprasidone—Asthenia—Epirubicin—urinary bladder cancer	0.000134	0.000224	CcSEcCtD
Ziprasidone—Dizziness—Methotrexate—urinary bladder cancer	0.000132	0.00022	CcSEcCtD
Ziprasidone—Diarrhoea—Epirubicin—urinary bladder cancer	0.000128	0.000213	CcSEcCtD
Ziprasidone—Hypersensitivity—Doxorubicin—urinary bladder cancer	0.000127	0.000213	CcSEcCtD
Ziprasidone—Vomiting—Methotrexate—urinary bladder cancer	0.000127	0.000212	CcSEcCtD
Ziprasidone—Rash—Methotrexate—urinary bladder cancer	0.000126	0.00021	CcSEcCtD
Ziprasidone—Dermatitis—Methotrexate—urinary bladder cancer	0.000126	0.00021	CcSEcCtD
Ziprasidone—Headache—Methotrexate—urinary bladder cancer	0.000125	0.000209	CcSEcCtD
Ziprasidone—Asthenia—Doxorubicin—urinary bladder cancer	0.000124	0.000207	CcSEcCtD
Ziprasidone—Dizziness—Epirubicin—urinary bladder cancer	0.000123	0.000206	CcSEcCtD
Ziprasidone—Vomiting—Epirubicin—urinary bladder cancer	0.000119	0.000198	CcSEcCtD
Ziprasidone—Nausea—Methotrexate—urinary bladder cancer	0.000118	0.000198	CcSEcCtD
Ziprasidone—Diarrhoea—Doxorubicin—urinary bladder cancer	0.000118	0.000198	CcSEcCtD
Ziprasidone—Rash—Epirubicin—urinary bladder cancer	0.000118	0.000197	CcSEcCtD
Ziprasidone—Dermatitis—Epirubicin—urinary bladder cancer	0.000118	0.000197	CcSEcCtD
Ziprasidone—Headache—Epirubicin—urinary bladder cancer	0.000117	0.000195	CcSEcCtD
Ziprasidone—Dizziness—Doxorubicin—urinary bladder cancer	0.000114	0.000191	CcSEcCtD
Ziprasidone—Nausea—Epirubicin—urinary bladder cancer	0.000111	0.000185	CcSEcCtD
Ziprasidone—Vomiting—Doxorubicin—urinary bladder cancer	0.00011	0.000184	CcSEcCtD
Ziprasidone—Rash—Doxorubicin—urinary bladder cancer	0.000109	0.000182	CcSEcCtD
Ziprasidone—Dermatitis—Doxorubicin—urinary bladder cancer	0.000109	0.000182	CcSEcCtD
Ziprasidone—Headache—Doxorubicin—urinary bladder cancer	0.000108	0.000181	CcSEcCtD
Ziprasidone—Nausea—Doxorubicin—urinary bladder cancer	0.000103	0.000171	CcSEcCtD
Ziprasidone—CHRM4—Signaling Pathways—MYC—urinary bladder cancer	1.09e-05	8.21e-05	CbGpPWpGaD
Ziprasidone—HTR2C—Signaling Pathways—IL2—urinary bladder cancer	1.08e-05	8.2e-05	CbGpPWpGaD
Ziprasidone—CYP1A2—Metabolism—GSTM1—urinary bladder cancer	1.08e-05	8.18e-05	CbGpPWpGaD
Ziprasidone—CYP1A2—Metabolism—NCOR1—urinary bladder cancer	1.08e-05	8.18e-05	CbGpPWpGaD
Ziprasidone—ADRA1B—Signaling by GPCR—HRAS—urinary bladder cancer	1.08e-05	8.16e-05	CbGpPWpGaD
Ziprasidone—DRD4—Signaling Pathways—EGFR—urinary bladder cancer	1.08e-05	8.14e-05	CbGpPWpGaD
Ziprasidone—ADRA2B—Signaling Pathways—MMP9—urinary bladder cancer	1.07e-05	8.08e-05	CbGpPWpGaD
Ziprasidone—ADRA2B—Signaling Pathways—CDKN1A—urinary bladder cancer	1.06e-05	8.05e-05	CbGpPWpGaD
Ziprasidone—HTR6—Signaling Pathways—KRAS—urinary bladder cancer	1.06e-05	8.04e-05	CbGpPWpGaD
Ziprasidone—HTR7—Signaling Pathways—KRAS—urinary bladder cancer	1.06e-05	8.04e-05	CbGpPWpGaD
Ziprasidone—HTR1A—Signaling Pathways—CCND1—urinary bladder cancer	1.06e-05	8.03e-05	CbGpPWpGaD
Ziprasidone—ADRA2B—Signaling Pathways—PTEN—urinary bladder cancer	1.06e-05	8.03e-05	CbGpPWpGaD
Ziprasidone—CHRM4—Signaling Pathways—EGFR—urinary bladder cancer	1.06e-05	8.03e-05	CbGpPWpGaD
Ziprasidone—HTR2C—Signaling Pathways—CCND1—urinary bladder cancer	1.06e-05	7.99e-05	CbGpPWpGaD
Ziprasidone—DRD2—Signaling Pathways—ERBB2—urinary bladder cancer	1.06e-05	7.98e-05	CbGpPWpGaD
Ziprasidone—HTR1D—Signaling Pathways—KRAS—urinary bladder cancer	1.06e-05	7.98e-05	CbGpPWpGaD
Ziprasidone—ADRA2C—Signaling Pathways—IL2—urinary bladder cancer	1.05e-05	7.98e-05	CbGpPWpGaD
Ziprasidone—CHRM3—Metabolism—PTEN—urinary bladder cancer	1.05e-05	7.94e-05	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling by GPCR—KRAS—urinary bladder cancer	1.05e-05	7.92e-05	CbGpPWpGaD
Ziprasidone—CHRM5—Signaling Pathways—MYC—urinary bladder cancer	1.04e-05	7.87e-05	CbGpPWpGaD
Ziprasidone—HTR2A—Signaling Pathways—ERBB2—urinary bladder cancer	1.04e-05	7.86e-05	CbGpPWpGaD
Ziprasidone—ADRA1B—Signaling Pathways—IL2—urinary bladder cancer	1.04e-05	7.85e-05	CbGpPWpGaD
Ziprasidone—HRH1—Signaling Pathways—ERBB2—urinary bladder cancer	1.04e-05	7.84e-05	CbGpPWpGaD
Ziprasidone—CYP1A2—Metabolism—GPX1—urinary bladder cancer	1.04e-05	7.84e-05	CbGpPWpGaD
Ziprasidone—HTR1B—Signaling Pathways—KRAS—urinary bladder cancer	1.03e-05	7.82e-05	CbGpPWpGaD
Ziprasidone—CHRM1—Signaling Pathways—ERBB2—urinary bladder cancer	1.03e-05	7.81e-05	CbGpPWpGaD
Ziprasidone—HTR1A—Signaling Pathways—MMP9—urinary bladder cancer	1.03e-05	7.8e-05	CbGpPWpGaD
Ziprasidone—CHRM3—Signaling Pathways—ERBB2—urinary bladder cancer	1.03e-05	7.79e-05	CbGpPWpGaD
Ziprasidone—ADRA2C—Signaling Pathways—CCND1—urinary bladder cancer	1.03e-05	7.77e-05	CbGpPWpGaD
Ziprasidone—HTR1A—Signaling Pathways—CDKN1A—urinary bladder cancer	1.03e-05	7.77e-05	CbGpPWpGaD
Ziprasidone—HTR2C—Signaling Pathways—MMP9—urinary bladder cancer	1.03e-05	7.76e-05	CbGpPWpGaD
Ziprasidone—HTR1A—Signaling Pathways—PTEN—urinary bladder cancer	1.03e-05	7.76e-05	CbGpPWpGaD
Ziprasidone—HTR2C—Signaling Pathways—CDKN1A—urinary bladder cancer	1.02e-05	7.73e-05	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling Pathways—RHOA—urinary bladder cancer	1.02e-05	7.72e-05	CbGpPWpGaD
Ziprasidone—HTR2C—Signaling Pathways—PTEN—urinary bladder cancer	1.02e-05	7.72e-05	CbGpPWpGaD
Ziprasidone—CHRM2—Signaling Pathways—ERBB2—urinary bladder cancer	1.02e-05	7.71e-05	CbGpPWpGaD
Ziprasidone—CYP1A2—Metabolism—ERCC2—urinary bladder cancer	1.02e-05	7.7e-05	CbGpPWpGaD
Ziprasidone—CHRM5—Signaling Pathways—EGFR—urinary bladder cancer	1.02e-05	7.69e-05	CbGpPWpGaD
Ziprasidone—ADRA1A—Signaling Pathways—ERBB2—urinary bladder cancer	1.02e-05	7.69e-05	CbGpPWpGaD
Ziprasidone—DRD4—Signaling Pathways—KRAS—urinary bladder cancer	1.02e-05	7.69e-05	CbGpPWpGaD
Ziprasidone—ADRA2B—Signaling Pathways—EP300—urinary bladder cancer	1.01e-05	7.66e-05	CbGpPWpGaD
Ziprasidone—CYP3A5—Metabolism—PTGS2—urinary bladder cancer	1.01e-05	7.66e-05	CbGpPWpGaD
Ziprasidone—ADRA1B—Signaling Pathways—CCND1—urinary bladder cancer	1.01e-05	7.65e-05	CbGpPWpGaD
Ziprasidone—CHRM4—Signaling Pathways—KRAS—urinary bladder cancer	1e-05	7.59e-05	CbGpPWpGaD
Ziprasidone—CHRM3—Metabolism—EP300—urinary bladder cancer	1e-05	7.58e-05	CbGpPWpGaD
Ziprasidone—DRD2—Signaling Pathways—CXCL8—urinary bladder cancer	1e-05	7.57e-05	CbGpPWpGaD
Ziprasidone—ADRA2C—Signaling Pathways—MMP9—urinary bladder cancer	9.98e-06	7.55e-05	CbGpPWpGaD
Ziprasidone—DRD2—Signaling by GPCR—HRAS—urinary bladder cancer	9.95e-06	7.52e-05	CbGpPWpGaD
Ziprasidone—ADRA2C—Signaling Pathways—CDKN1A—urinary bladder cancer	9.95e-06	7.52e-05	CbGpPWpGaD
Ziprasidone—ADRA2C—Signaling Pathways—PTEN—urinary bladder cancer	9.93e-06	7.5e-05	CbGpPWpGaD
Ziprasidone—DRD1—Signaling Pathways—MYC—urinary bladder cancer	9.91e-06	7.49e-05	CbGpPWpGaD
Ziprasidone—HTR2A—Signaling Pathways—CXCL8—urinary bladder cancer	9.85e-06	7.45e-05	CbGpPWpGaD
Ziprasidone—ADRA2B—Signaling Pathways—SRC—urinary bladder cancer	9.85e-06	7.45e-05	CbGpPWpGaD
Ziprasidone—HRH1—Signaling Pathways—CXCL8—urinary bladder cancer	9.83e-06	7.43e-05	CbGpPWpGaD
Ziprasidone—ADRA1B—Signaling Pathways—MMP9—urinary bladder cancer	9.83e-06	7.43e-05	CbGpPWpGaD
Ziprasidone—CHRM1—Signaling Pathways—CXCL8—urinary bladder cancer	9.8e-06	7.41e-05	CbGpPWpGaD
Ziprasidone—HTR2A—Signaling by GPCR—HRAS—urinary bladder cancer	9.79e-06	7.4e-05	CbGpPWpGaD
Ziprasidone—ADRA1B—Signaling Pathways—CDKN1A—urinary bladder cancer	9.79e-06	7.4e-05	CbGpPWpGaD
Ziprasidone—HTR1A—Signaling Pathways—EP300—urinary bladder cancer	9.78e-06	7.4e-05	CbGpPWpGaD
Ziprasidone—DRD3—Signaling Pathways—MYC—urinary bladder cancer	9.78e-06	7.39e-05	CbGpPWpGaD
Ziprasidone—CHRM3—Signaling Pathways—CXCL8—urinary bladder cancer	9.77e-06	7.39e-05	CbGpPWpGaD
Ziprasidone—HRH1—Signaling by GPCR—HRAS—urinary bladder cancer	9.77e-06	7.39e-05	CbGpPWpGaD
Ziprasidone—ADRA1B—Signaling Pathways—PTEN—urinary bladder cancer	9.77e-06	7.39e-05	CbGpPWpGaD
Ziprasidone—CHRM1—Signaling by GPCR—HRAS—urinary bladder cancer	9.74e-06	7.36e-05	CbGpPWpGaD
Ziprasidone—HTR2C—Signaling Pathways—EP300—urinary bladder cancer	9.73e-06	7.36e-05	CbGpPWpGaD
Ziprasidone—CHRM3—Signaling by GPCR—HRAS—urinary bladder cancer	9.71e-06	7.34e-05	CbGpPWpGaD
Ziprasidone—DRD1—Signaling Pathways—EGFR—urinary bladder cancer	9.7e-06	7.33e-05	CbGpPWpGaD
Ziprasidone—CHRM2—Signaling Pathways—CXCL8—urinary bladder cancer	9.68e-06	7.32e-05	CbGpPWpGaD
Ziprasidone—ADRA1A—Signaling Pathways—CXCL8—urinary bladder cancer	9.65e-06	7.3e-05	CbGpPWpGaD
Ziprasidone—ADRA2A—Metabolism—PTEN—urinary bladder cancer	9.64e-06	7.29e-05	CbGpPWpGaD
Ziprasidone—CHRM2—Signaling by GPCR—HRAS—urinary bladder cancer	9.61e-06	7.27e-05	CbGpPWpGaD
Ziprasidone—CHRM5—Signaling Pathways—KRAS—urinary bladder cancer	9.61e-06	7.27e-05	CbGpPWpGaD
Ziprasidone—ADRA1A—Signaling by GPCR—HRAS—urinary bladder cancer	9.59e-06	7.25e-05	CbGpPWpGaD
Ziprasidone—DRD2—Signaling Pathways—IL2—urinary bladder cancer	9.57e-06	7.24e-05	CbGpPWpGaD
Ziprasidone—CYP1A2—Metabolism—MTHFR—urinary bladder cancer	9.57e-06	7.23e-05	CbGpPWpGaD
Ziprasidone—DRD3—Signaling Pathways—EGFR—urinary bladder cancer	9.57e-06	7.23e-05	CbGpPWpGaD
Ziprasidone—HTR1A—Signaling Pathways—SRC—urinary bladder cancer	9.51e-06	7.19e-05	CbGpPWpGaD
Ziprasidone—ADRA2C—Signaling Pathways—EP300—urinary bladder cancer	9.47e-06	7.16e-05	CbGpPWpGaD
Ziprasidone—HTR2C—Signaling Pathways—SRC—urinary bladder cancer	9.46e-06	7.15e-05	CbGpPWpGaD
Ziprasidone—HTR6—Signaling Pathways—TP53—urinary bladder cancer	9.46e-06	7.15e-05	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling Pathways—ERBB2—urinary bladder cancer	9.45e-06	7.15e-05	CbGpPWpGaD
Ziprasidone—HTR7—Signaling Pathways—TP53—urinary bladder cancer	9.45e-06	7.14e-05	CbGpPWpGaD
Ziprasidone—HTR2A—Signaling Pathways—IL2—urinary bladder cancer	9.42e-06	7.12e-05	CbGpPWpGaD
Ziprasidone—HRH1—Signaling Pathways—IL2—urinary bladder cancer	9.4e-06	7.11e-05	CbGpPWpGaD
Ziprasidone—HTR1D—Signaling Pathways—TP53—urinary bladder cancer	9.39e-06	7.1e-05	CbGpPWpGaD
Ziprasidone—CHRM1—Signaling Pathways—IL2—urinary bladder cancer	9.37e-06	7.08e-05	CbGpPWpGaD
Ziprasidone—CHRM3—Signaling Pathways—IL2—urinary bladder cancer	9.34e-06	7.06e-05	CbGpPWpGaD
Ziprasidone—DRD2—Signaling Pathways—CCND1—urinary bladder cancer	9.33e-06	7.05e-05	CbGpPWpGaD
Ziprasidone—ADRA1B—Signaling Pathways—EP300—urinary bladder cancer	9.32e-06	7.04e-05	CbGpPWpGaD
Ziprasidone—CHRM2—Signaling Pathways—IL2—urinary bladder cancer	9.25e-06	6.99e-05	CbGpPWpGaD
Ziprasidone—ADRA1A—Signaling Pathways—IL2—urinary bladder cancer	9.22e-06	6.97e-05	CbGpPWpGaD
Ziprasidone—ADRA2C—Signaling Pathways—SRC—urinary bladder cancer	9.2e-06	6.96e-05	CbGpPWpGaD
Ziprasidone—ADRA2A—Metabolism—EP300—urinary bladder cancer	9.19e-06	6.95e-05	CbGpPWpGaD
Ziprasidone—HTR1B—Signaling Pathways—TP53—urinary bladder cancer	9.19e-06	6.95e-05	CbGpPWpGaD
Ziprasidone—HTR2A—Signaling Pathways—CCND1—urinary bladder cancer	9.18e-06	6.94e-05	CbGpPWpGaD
Ziprasidone—HRH1—Signaling Pathways—CCND1—urinary bladder cancer	9.16e-06	6.93e-05	CbGpPWpGaD
Ziprasidone—DRD1—Signaling Pathways—KRAS—urinary bladder cancer	9.16e-06	6.93e-05	CbGpPWpGaD
Ziprasidone—CYP2D6—Metabolism—PPARG—urinary bladder cancer	9.16e-06	6.92e-05	CbGpPWpGaD
Ziprasidone—CHRM1—Signaling Pathways—CCND1—urinary bladder cancer	9.13e-06	6.9e-05	CbGpPWpGaD
Ziprasidone—CHRM3—Signaling Pathways—CCND1—urinary bladder cancer	9.1e-06	6.88e-05	CbGpPWpGaD
Ziprasidone—CYP3A4—Metabolism—GSTP1—urinary bladder cancer	9.09e-06	6.87e-05	CbGpPWpGaD
Ziprasidone—ADRA1B—Signaling Pathways—SRC—urinary bladder cancer	9.06e-06	6.85e-05	CbGpPWpGaD
Ziprasidone—DRD2—Signaling Pathways—MMP9—urinary bladder cancer	9.06e-06	6.85e-05	CbGpPWpGaD
Ziprasidone—HTR6—Signaling Pathways—HRAS—urinary bladder cancer	9.04e-06	6.84e-05	CbGpPWpGaD
Ziprasidone—DRD4—Signaling Pathways—TP53—urinary bladder cancer	9.04e-06	6.84e-05	CbGpPWpGaD
Ziprasidone—DRD3—Signaling Pathways—KRAS—urinary bladder cancer	9.04e-06	6.83e-05	CbGpPWpGaD
Ziprasidone—HTR7—Signaling Pathways—HRAS—urinary bladder cancer	9.03e-06	6.83e-05	CbGpPWpGaD
Ziprasidone—DRD2—Signaling Pathways—CDKN1A—urinary bladder cancer	9.03e-06	6.82e-05	CbGpPWpGaD
Ziprasidone—CHRM2—Signaling Pathways—CCND1—urinary bladder cancer	9.01e-06	6.82e-05	CbGpPWpGaD
Ziprasidone—DRD2—Signaling Pathways—PTEN—urinary bladder cancer	9.01e-06	6.81e-05	CbGpPWpGaD
Ziprasidone—ADRA1A—Signaling Pathways—CCND1—urinary bladder cancer	8.99e-06	6.8e-05	CbGpPWpGaD
Ziprasidone—HTR1D—Signaling Pathways—HRAS—urinary bladder cancer	8.98e-06	6.79e-05	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling Pathways—CXCL8—urinary bladder cancer	8.97e-06	6.78e-05	CbGpPWpGaD
Ziprasidone—CHRM4—Signaling Pathways—TP53—urinary bladder cancer	8.92e-06	6.74e-05	CbGpPWpGaD
Ziprasidone—HTR2A—Signaling Pathways—MMP9—urinary bladder cancer	8.91e-06	6.74e-05	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling by GPCR—HRAS—urinary bladder cancer	8.91e-06	6.73e-05	CbGpPWpGaD
Ziprasidone—HRH1—Signaling Pathways—MMP9—urinary bladder cancer	8.89e-06	6.72e-05	CbGpPWpGaD
Ziprasidone—HTR2A—Signaling Pathways—CDKN1A—urinary bladder cancer	8.88e-06	6.71e-05	CbGpPWpGaD
Ziprasidone—CHRM1—Signaling Pathways—MMP9—urinary bladder cancer	8.87e-06	6.7e-05	CbGpPWpGaD
Ziprasidone—HRH1—Signaling Pathways—CDKN1A—urinary bladder cancer	8.86e-06	6.7e-05	CbGpPWpGaD
Ziprasidone—HTR2A—Signaling Pathways—PTEN—urinary bladder cancer	8.86e-06	6.7e-05	CbGpPWpGaD
Ziprasidone—HRH1—Signaling Pathways—PTEN—urinary bladder cancer	8.84e-06	6.69e-05	CbGpPWpGaD
Ziprasidone—CHRM3—Signaling Pathways—MMP9—urinary bladder cancer	8.84e-06	6.68e-05	CbGpPWpGaD
Ziprasidone—CYP3A5—Metabolism—PTEN—urinary bladder cancer	8.84e-06	6.68e-05	CbGpPWpGaD
Ziprasidone—CHRM1—Signaling Pathways—CDKN1A—urinary bladder cancer	8.83e-06	6.68e-05	CbGpPWpGaD
Ziprasidone—ADRA2B—Signaling Pathways—MYC—urinary bladder cancer	8.83e-06	6.68e-05	CbGpPWpGaD
Ziprasidone—CHRM1—Signaling Pathways—PTEN—urinary bladder cancer	8.81e-06	6.66e-05	CbGpPWpGaD
Ziprasidone—CHRM3—Signaling Pathways—CDKN1A—urinary bladder cancer	8.81e-06	6.66e-05	CbGpPWpGaD
Ziprasidone—CYP2D6—Metabolism—CREBBP—urinary bladder cancer	8.8e-06	6.65e-05	CbGpPWpGaD
Ziprasidone—HTR1B—Signaling Pathways—HRAS—urinary bladder cancer	8.79e-06	6.64e-05	CbGpPWpGaD
Ziprasidone—CHRM3—Signaling Pathways—PTEN—urinary bladder cancer	8.79e-06	6.64e-05	CbGpPWpGaD
Ziprasidone—CHRM2—Signaling Pathways—MMP9—urinary bladder cancer	8.75e-06	6.62e-05	CbGpPWpGaD
Ziprasidone—ADRA1A—Signaling Pathways—MMP9—urinary bladder cancer	8.73e-06	6.6e-05	CbGpPWpGaD
Ziprasidone—CHRM2—Signaling Pathways—CDKN1A—urinary bladder cancer	8.72e-06	6.59e-05	CbGpPWpGaD
Ziprasidone—CHRM2—Signaling Pathways—PTEN—urinary bladder cancer	8.7e-06	6.58e-05	CbGpPWpGaD
Ziprasidone—ADRA1A—Signaling Pathways—CDKN1A—urinary bladder cancer	8.7e-06	6.57e-05	CbGpPWpGaD
Ziprasidone—ADRA1A—Signaling Pathways—PTEN—urinary bladder cancer	8.68e-06	6.56e-05	CbGpPWpGaD
Ziprasidone—DRD4—Signaling Pathways—HRAS—urinary bladder cancer	8.65e-06	6.54e-05	CbGpPWpGaD
Ziprasidone—ADRA2B—Signaling Pathways—EGFR—urinary bladder cancer	8.64e-06	6.53e-05	CbGpPWpGaD
Ziprasidone—DRD2—Signaling Pathways—EP300—urinary bladder cancer	8.59e-06	6.49e-05	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling Pathways—IL2—urinary bladder cancer	8.57e-06	6.48e-05	CbGpPWpGaD
Ziprasidone—CHRM5—Signaling Pathways—TP53—urinary bladder cancer	8.54e-06	6.46e-05	CbGpPWpGaD
Ziprasidone—CHRM4—Signaling Pathways—HRAS—urinary bladder cancer	8.53e-06	6.45e-05	CbGpPWpGaD
Ziprasidone—HTR1A—Signaling Pathways—MYC—urinary bladder cancer	8.52e-06	6.44e-05	CbGpPWpGaD
Ziprasidone—HTR2C—Signaling Pathways—MYC—urinary bladder cancer	8.48e-06	6.41e-05	CbGpPWpGaD
Ziprasidone—CYP3A4—Metabolism—TYMS—urinary bladder cancer	8.45e-06	6.39e-05	CbGpPWpGaD
Ziprasidone—HTR2A—Signaling Pathways—EP300—urinary bladder cancer	8.45e-06	6.39e-05	CbGpPWpGaD
Ziprasidone—HRH1—Signaling Pathways—EP300—urinary bladder cancer	8.43e-06	6.38e-05	CbGpPWpGaD
Ziprasidone—CYP3A5—Metabolism—EP300—urinary bladder cancer	8.43e-06	6.37e-05	CbGpPWpGaD
Ziprasidone—CHRM1—Signaling Pathways—EP300—urinary bladder cancer	8.41e-06	6.36e-05	CbGpPWpGaD
Ziprasidone—CHRM3—Signaling Pathways—EP300—urinary bladder cancer	8.38e-06	6.33e-05	CbGpPWpGaD
Ziprasidone—CYP3A4—Metabolism—GSTM1—urinary bladder cancer	8.35e-06	6.32e-05	CbGpPWpGaD
Ziprasidone—CYP3A4—Metabolism—NCOR1—urinary bladder cancer	8.35e-06	6.32e-05	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling Pathways—CCND1—urinary bladder cancer	8.35e-06	6.32e-05	CbGpPWpGaD
Ziprasidone—DRD2—Signaling Pathways—SRC—urinary bladder cancer	8.35e-06	6.31e-05	CbGpPWpGaD
Ziprasidone—HTR1A—Signaling Pathways—EGFR—urinary bladder cancer	8.34e-06	6.3e-05	CbGpPWpGaD
Ziprasidone—CHRM2—Signaling Pathways—EP300—urinary bladder cancer	8.3e-06	6.27e-05	CbGpPWpGaD
Ziprasidone—HTR2C—Signaling Pathways—EGFR—urinary bladder cancer	8.29e-06	6.27e-05	CbGpPWpGaD
Ziprasidone—ADRA1A—Signaling Pathways—EP300—urinary bladder cancer	8.27e-06	6.26e-05	CbGpPWpGaD
Ziprasidone—ADRA2C—Signaling Pathways—MYC—urinary bladder cancer	8.25e-06	6.24e-05	CbGpPWpGaD
Ziprasidone—HTR2A—Signaling Pathways—SRC—urinary bladder cancer	8.22e-06	6.21e-05	CbGpPWpGaD
Ziprasidone—HRH1—Signaling Pathways—SRC—urinary bladder cancer	8.2e-06	6.2e-05	CbGpPWpGaD
Ziprasidone—CHRM1—Signaling Pathways—SRC—urinary bladder cancer	8.17e-06	6.18e-05	CbGpPWpGaD
Ziprasidone—CHRM5—Signaling Pathways—HRAS—urinary bladder cancer	8.17e-06	6.18e-05	CbGpPWpGaD
Ziprasidone—ADRA2B—Signaling Pathways—KRAS—urinary bladder cancer	8.16e-06	6.17e-05	CbGpPWpGaD
Ziprasidone—CHRM3—Signaling Pathways—SRC—urinary bladder cancer	8.15e-06	6.16e-05	CbGpPWpGaD
Ziprasidone—DRD1—Signaling Pathways—TP53—urinary bladder cancer	8.14e-06	6.15e-05	CbGpPWpGaD
Ziprasidone—ADRA1B—Signaling Pathways—MYC—urinary bladder cancer	8.12e-06	6.14e-05	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling Pathways—MMP9—urinary bladder cancer	8.11e-06	6.13e-05	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling Pathways—CDKN1A—urinary bladder cancer	8.08e-06	6.11e-05	CbGpPWpGaD
Ziprasidone—CHRM2—Signaling Pathways—SRC—urinary bladder cancer	8.07e-06	6.1e-05	CbGpPWpGaD
Ziprasidone—ADRA2C—Signaling Pathways—EGFR—urinary bladder cancer	8.07e-06	6.1e-05	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling Pathways—PTEN—urinary bladder cancer	8.06e-06	6.1e-05	CbGpPWpGaD
Ziprasidone—ADRA1A—Signaling Pathways—SRC—urinary bladder cancer	8.05e-06	6.08e-05	CbGpPWpGaD
Ziprasidone—DRD3—Signaling Pathways—TP53—urinary bladder cancer	8.03e-06	6.07e-05	CbGpPWpGaD
Ziprasidone—CYP3A4—Metabolism—GPX1—urinary bladder cancer	8e-06	6.05e-05	CbGpPWpGaD
Ziprasidone—ADRA1B—Signaling Pathways—EGFR—urinary bladder cancer	7.94e-06	6e-05	CbGpPWpGaD
Ziprasidone—HTR1A—Signaling Pathways—KRAS—urinary bladder cancer	7.88e-06	5.95e-05	CbGpPWpGaD
Ziprasidone—CYP3A4—Metabolism—ERCC2—urinary bladder cancer	7.86e-06	5.94e-05	CbGpPWpGaD
Ziprasidone—HTR2C—Signaling Pathways—KRAS—urinary bladder cancer	7.84e-06	5.92e-05	CbGpPWpGaD
Ziprasidone—DRD1—Signaling Pathways—HRAS—urinary bladder cancer	7.79e-06	5.89e-05	CbGpPWpGaD
Ziprasidone—CYP1A2—Metabolism—PPARG—urinary bladder cancer	7.76e-06	5.87e-05	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling Pathways—EP300—urinary bladder cancer	7.69e-06	5.81e-05	CbGpPWpGaD
Ziprasidone—DRD3—Signaling Pathways—HRAS—urinary bladder cancer	7.68e-06	5.81e-05	CbGpPWpGaD
Ziprasidone—ADRA2C—Signaling Pathways—KRAS—urinary bladder cancer	7.62e-06	5.76e-05	CbGpPWpGaD
Ziprasidone—ADRA1B—Signaling Pathways—KRAS—urinary bladder cancer	7.5e-06	5.67e-05	CbGpPWpGaD
Ziprasidone—DRD2—Signaling Pathways—MYC—urinary bladder cancer	7.48e-06	5.66e-05	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling Pathways—SRC—urinary bladder cancer	7.48e-06	5.65e-05	CbGpPWpGaD
Ziprasidone—CYP1A2—Metabolism—CREBBP—urinary bladder cancer	7.45e-06	5.63e-05	CbGpPWpGaD
Ziprasidone—CYP3A4—Metabolism—MTHFR—urinary bladder cancer	7.38e-06	5.58e-05	CbGpPWpGaD
Ziprasidone—HTR2A—Signaling Pathways—MYC—urinary bladder cancer	7.36e-06	5.57e-05	CbGpPWpGaD
Ziprasidone—HRH1—Signaling Pathways—MYC—urinary bladder cancer	7.35e-06	5.56e-05	CbGpPWpGaD
Ziprasidone—CHRM1—Signaling Pathways—MYC—urinary bladder cancer	7.32e-06	5.54e-05	CbGpPWpGaD
Ziprasidone—DRD2—Signaling Pathways—EGFR—urinary bladder cancer	7.32e-06	5.53e-05	CbGpPWpGaD
Ziprasidone—CHRM3—Signaling Pathways—MYC—urinary bladder cancer	7.3e-06	5.52e-05	CbGpPWpGaD
Ziprasidone—ADRA2B—Signaling Pathways—TP53—urinary bladder cancer	7.25e-06	5.48e-05	CbGpPWpGaD
Ziprasidone—CHRM2—Signaling Pathways—MYC—urinary bladder cancer	7.23e-06	5.47e-05	CbGpPWpGaD
Ziprasidone—ADRA1A—Signaling Pathways—MYC—urinary bladder cancer	7.21e-06	5.45e-05	CbGpPWpGaD
Ziprasidone—CYP2D6—Metabolism—PTGS2—urinary bladder cancer	7.2e-06	5.45e-05	CbGpPWpGaD
Ziprasidone—HTR2A—Signaling Pathways—EGFR—urinary bladder cancer	7.2e-06	5.45e-05	CbGpPWpGaD
Ziprasidone—HRH1—Signaling Pathways—EGFR—urinary bladder cancer	7.19e-06	5.43e-05	CbGpPWpGaD
Ziprasidone—CHRM1—Signaling Pathways—EGFR—urinary bladder cancer	7.16e-06	5.42e-05	CbGpPWpGaD
Ziprasidone—CHRM3—Signaling Pathways—EGFR—urinary bladder cancer	7.14e-06	5.4e-05	CbGpPWpGaD
Ziprasidone—CHRM2—Signaling Pathways—EGFR—urinary bladder cancer	7.07e-06	5.35e-05	CbGpPWpGaD
Ziprasidone—ADRA1A—Signaling Pathways—EGFR—urinary bladder cancer	7.05e-06	5.33e-05	CbGpPWpGaD
Ziprasidone—HTR1A—Signaling Pathways—TP53—urinary bladder cancer	7e-06	5.29e-05	CbGpPWpGaD
Ziprasidone—HTR2C—Signaling Pathways—TP53—urinary bladder cancer	6.96e-06	5.27e-05	CbGpPWpGaD
Ziprasidone—ADRA2B—Signaling Pathways—HRAS—urinary bladder cancer	6.94e-06	5.24e-05	CbGpPWpGaD
Ziprasidone—DRD2—Signaling Pathways—KRAS—urinary bladder cancer	6.92e-06	5.23e-05	CbGpPWpGaD
Ziprasidone—HTR2A—Signaling Pathways—KRAS—urinary bladder cancer	6.8e-06	5.14e-05	CbGpPWpGaD
Ziprasidone—HRH1—Signaling Pathways—KRAS—urinary bladder cancer	6.79e-06	5.13e-05	CbGpPWpGaD
Ziprasidone—ADRA2C—Signaling Pathways—TP53—urinary bladder cancer	6.77e-06	5.12e-05	CbGpPWpGaD
Ziprasidone—CHRM1—Signaling Pathways—KRAS—urinary bladder cancer	6.77e-06	5.12e-05	CbGpPWpGaD
Ziprasidone—CHRM3—Signaling Pathways—KRAS—urinary bladder cancer	6.75e-06	5.1e-05	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling Pathways—MYC—urinary bladder cancer	6.7e-06	5.07e-05	CbGpPWpGaD
Ziprasidone—HTR1A—Signaling Pathways—HRAS—urinary bladder cancer	6.69e-06	5.06e-05	CbGpPWpGaD
Ziprasidone—CHRM2—Signaling Pathways—KRAS—urinary bladder cancer	6.68e-06	5.05e-05	CbGpPWpGaD
Ziprasidone—ADRA1B—Signaling Pathways—TP53—urinary bladder cancer	6.67e-06	5.04e-05	CbGpPWpGaD
Ziprasidone—ADRA1A—Signaling Pathways—KRAS—urinary bladder cancer	6.66e-06	5.04e-05	CbGpPWpGaD
Ziprasidone—HTR2C—Signaling Pathways—HRAS—urinary bladder cancer	6.66e-06	5.04e-05	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling Pathways—EGFR—urinary bladder cancer	6.55e-06	4.95e-05	CbGpPWpGaD
Ziprasidone—ADRA2C—Signaling Pathways—HRAS—urinary bladder cancer	6.48e-06	4.9e-05	CbGpPWpGaD
Ziprasidone—ADRA1B—Signaling Pathways—HRAS—urinary bladder cancer	6.38e-06	4.82e-05	CbGpPWpGaD
Ziprasidone—CYP2D6—Metabolism—PTEN—urinary bladder cancer	6.28e-06	4.75e-05	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling Pathways—KRAS—urinary bladder cancer	6.19e-06	4.68e-05	CbGpPWpGaD
Ziprasidone—DRD2—Signaling Pathways—TP53—urinary bladder cancer	6.15e-06	4.65e-05	CbGpPWpGaD
Ziprasidone—CYP1A2—Metabolism—PTGS2—urinary bladder cancer	6.1e-06	4.61e-05	CbGpPWpGaD
Ziprasidone—HTR2A—Signaling Pathways—TP53—urinary bladder cancer	6.05e-06	4.57e-05	CbGpPWpGaD
Ziprasidone—HRH1—Signaling Pathways—TP53—urinary bladder cancer	6.03e-06	4.56e-05	CbGpPWpGaD
Ziprasidone—CHRM1—Signaling Pathways—TP53—urinary bladder cancer	6.02e-06	4.55e-05	CbGpPWpGaD
Ziprasidone—CHRM3—Signaling Pathways—TP53—urinary bladder cancer	6e-06	4.53e-05	CbGpPWpGaD
Ziprasidone—CYP2D6—Metabolism—EP300—urinary bladder cancer	5.99e-06	4.53e-05	CbGpPWpGaD
Ziprasidone—CYP3A4—Metabolism—PPARG—urinary bladder cancer	5.99e-06	4.53e-05	CbGpPWpGaD
Ziprasidone—CHRM2—Signaling Pathways—TP53—urinary bladder cancer	5.94e-06	4.49e-05	CbGpPWpGaD
Ziprasidone—ADRA1A—Signaling Pathways—TP53—urinary bladder cancer	5.92e-06	4.48e-05	CbGpPWpGaD
Ziprasidone—DRD2—Signaling Pathways—HRAS—urinary bladder cancer	5.88e-06	4.44e-05	CbGpPWpGaD
Ziprasidone—HTR2A—Signaling Pathways—HRAS—urinary bladder cancer	5.78e-06	4.37e-05	CbGpPWpGaD
Ziprasidone—HRH1—Signaling Pathways—HRAS—urinary bladder cancer	5.77e-06	4.36e-05	CbGpPWpGaD
Ziprasidone—CHRM1—Signaling Pathways—HRAS—urinary bladder cancer	5.75e-06	4.35e-05	CbGpPWpGaD
Ziprasidone—CYP3A4—Metabolism—CREBBP—urinary bladder cancer	5.75e-06	4.35e-05	CbGpPWpGaD
Ziprasidone—CHRM3—Signaling Pathways—HRAS—urinary bladder cancer	5.73e-06	4.34e-05	CbGpPWpGaD
Ziprasidone—CHRM2—Signaling Pathways—HRAS—urinary bladder cancer	5.68e-06	4.29e-05	CbGpPWpGaD
Ziprasidone—ADRA1A—Signaling Pathways—HRAS—urinary bladder cancer	5.66e-06	4.28e-05	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling Pathways—TP53—urinary bladder cancer	5.5e-06	4.16e-05	CbGpPWpGaD
Ziprasidone—CYP1A2—Metabolism—PTEN—urinary bladder cancer	5.32e-06	4.02e-05	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling Pathways—HRAS—urinary bladder cancer	5.26e-06	3.98e-05	CbGpPWpGaD
Ziprasidone—CYP1A2—Metabolism—EP300—urinary bladder cancer	5.08e-06	3.84e-05	CbGpPWpGaD
Ziprasidone—CYP3A4—Metabolism—PTGS2—urinary bladder cancer	4.71e-06	3.56e-05	CbGpPWpGaD
Ziprasidone—CYP3A4—Metabolism—PTEN—urinary bladder cancer	4.11e-06	3.11e-05	CbGpPWpGaD
Ziprasidone—CYP3A4—Metabolism—EP300—urinary bladder cancer	3.92e-06	2.96e-05	CbGpPWpGaD
